



Adoptive T-Cell Therapy against Solid Tumors

Guest Editor:

Prof. Dr. Niels Schaft

Department of Dermatology,
Universitätsklinikum Erlangen,
91054 Erlangen, Germany

Deadline for manuscript
submissions:

closed (30 November 2022)

Message from the Guest Editor

Dear Colleagues,

Tumor-antigen-specific cytotoxic T lymphocytes (CTL) play a key role in tumor immunology. Therefore, the generation of these cells to support the often-crippled immune system of the patient has been the main aim in the cellular adoptive immunotherapy of cancer. The transferred cells range from tumor-infiltrating lymphocytes (TIL) to T cells reprogrammed with a tumor-antigen specificity by transfer of a T-cell receptor (TCR) or chimeric antigen receptor (CAR). The latter strategy in particular has proven to be very efficient in the treatment of hematologic tumors. However, the efficacy against solid tumor lags behind. Therefore, this Special Issue will focus on improvements and new strategies of adoptive T-cell therapy against solid tumors.

Authors are cordially invited to contribute original research papers or reviews to this Special Issue of *Immuno*.

For further information about the topics of interest, please visit:

https://www.mdpi.com/journal/immuno/special_issues/tcell

Dr. Dr. habil. med. Niels Schaft
Guest Editor

